This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

AZD 2066 Single Dose Formulation and Food Effect Study in Healthy Volunteers

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: June 2, 2008
Last updated: December 8, 2010
Last verified: December 2010
A open label two way crossover formulation and food effect study in healthy volunteers to assess the pharmacokinetics of a single dose of AZD2066 new oral solid formulation and an oral solution

Condition Intervention Phase
Healthy Drug: AZD2066 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: A Phase 1, Single-center, Randomized, Open-label, Two-way Crossover, Formulation and Food Effect Study in Healthy Volunteers, to Assess the Pharmacokinetics of AZD 2066 After Single Doses of a New Oral Solid Formulation and an Oral Solution

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • AZ2066 pharmacokinetics [ Time Frame: several samples within 72 hrs ]

Secondary Outcome Measures:
  • Effect of food on AZD2066 pharmacokinetics [ Time Frame: several samples over 72 hrs ]

Enrollment: 20
Study Start Date: April 2008
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: AZD2066
single oral dose


Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Clinical normal physical findings, including BP, pulse rate >45 bpm, ECG and laboratory assessments
  • Body Mass Index (BMI) of ≥18 to ≤30 kg/m2 and weight of ≥50 to ≤100 kg

Exclusion Criteria:

  • History of hypersensitivity, allergy or atopic/skin disease as judged by Investigator.
  • History of somatic or psychiatric disease/condition, which may interfere with the objectives of the study as judged by the Investigator.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00690404

Sponsors and Collaborators
Principal Investigator: Eleanor Lisbon, MD, MPH Quintiles, Inc. Overland Park, Kansas, USA
Study Chair: Heather Wray, MB, ChB, FFPM AstraZeneca Charnwood England
Study Chair: Ivan Eggens, MD AstraZeneca , Södertälje, Sweden
  More Information

Responsible Party: Rolf Karlsten, M.D., Medical Science Director, Emerging Neuroscience, AstraZeneca Pharmaceuticals Identifier: NCT00690404     History of Changes
Other Study ID Numbers: D0475C00005
Study First Received: June 2, 2008
Last Updated: December 8, 2010

Keywords provided by AstraZeneca:
crossover formulation
food effect
oral solution
healthy volunteers processed this record on August 21, 2017